Pneumococcal Vaccine Market Size, Share, and Outlook, H2-2025 Report- By Vaccine (Pneumococcal conjugate vaccine, Pneumococcal polysaccharide vaccine), By Product (Prevnar 13, Synflorix, Pneumovax23), By Distribution Channel (Distribution partner companie
Description
Pneumococcal Vaccine Market Outlook
The global Pneumococcal Vaccine Market Size is valued at $8.9 Billion in 2025 and is forecast to reach $13.7 Billion in 2032 at a CAGR of 6.4%.
The Pneumococcal Vaccine Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Pneumococcal Vaccine Market segments across 22 countries from 2021 to 2032. Key segments covered include By Vaccine (Pneumococcal conjugate vaccine, Pneumococcal polysaccharide vaccine), By Product (Prevnar 13, Synflorix, Pneumovax23), By Distribution Channel (Distribution partner companies, Non-governmental Organizations, Government Authorities), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Pneumococcal Vaccine Market Insights, 2025
The pneumococcal vaccine market continues to expand, driven by enhanced vaccine formulations covering more serotypes and improved immunization strategies globally. Recent developments include next-generation conjugate vaccines with broader serotype coverage aimed at reducing invasive pneumococcal diseases across all age groups. The incorporation of protein-based antigens is under clinical evaluation to elicit longer-lasting immune responses. Efforts to improve vaccine accessibility in low- and middle-income countries have accelerated, supported by global health initiatives and partnerships. Innovations in delivery methods, including needle-free and thermostable formulations, are enhancing immunization coverage and compliance. The market is also adapting to the evolving epidemiology of pneumococcal strains influenced by vaccination campaigns. Regulatory bodies are increasingly focusing on post-marketing surveillance to monitor vaccine effectiveness and safety. The COVID-19 pandemic underscored the importance of respiratory disease prevention, further propelling pneumococcal vaccine demand.
Five Trends Shaping the Global Pneumococcal Vaccine Market in 2025 and Beyond
The global Pneumococcal Vaccine Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Pneumococcal Vaccine Industry?
The Pneumococcal Vaccine Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Pneumococcal Vaccine Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Pneumococcal Vaccine Market Segment Insights
The Pneumococcal Vaccine Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Vaccine (Pneumococcal conjugate vaccine, Pneumococcal polysaccharide vaccine), By Product (Prevnar 13, Synflorix, Pneumovax23), By Distribution Channel (Distribution partner companies, Non-governmental Organizations, Government Authorities). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Pneumococcal Vaccine Industry Value Chain
The chapter identifies potential companies and their operations across the global Pneumococcal Vaccine Industry ecosystem. It assists decision-makers in evaluating global Pneumococcal Vaccine Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Pneumococcal Vaccine Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Pneumococcal Vaccine Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Pneumococcal Vaccine Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Pneumococcal Vaccine Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Pneumococcal Vaccine Market.
Europe Pneumococcal Vaccine Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Pneumococcal Vaccine Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Pneumococcal Vaccine Industry competitiveness. The report analyses the key Pneumococcal Vaccine Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Pneumococcal Vaccine Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Pneumococcal Vaccine Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Pneumococcal Vaccine Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Pneumococcal Vaccine Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Pneumococcal Vaccine Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Pneumococcal Vaccine Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Beijing Minhai Biotechnology Co.,Ltd, CSL Ltd, GlaxoSmithKline plc, Merck KGaA, Pfizer Inc, Sanofi S.A, Serum Institute of India Pvt. Ltd, Walvax Biotechnology Co. Ltd. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Pneumococcal Vaccine Market Scope
Leading Segments
By Vaccine
Pneumococcal conjugate vaccine
Pneumococcal polysaccharide vaccine
By Product
Prevnar 13
Synflorix
Pneumovax23
By Distribution Channel
Distribution partner companies
Non-governmental Organizations
Government Authorities
Leading Companies
Beijing Minhai Biotechnology Co.,Ltd
CSL Ltd
GlaxoSmithKline plc
Merck KGaA
Pfizer Inc
Sanofi S.A
Serum Institute of India Pvt. Ltd
Walvax Biotechnology Co. Ltd
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report Make informed decisions with 12-year forecasts across 22 countries and multiple market segments. Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry. Gain insights into the competitive landscape, including company profiles, financials, and strategic moves. Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations. Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade. Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions. Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.
The global Pneumococcal Vaccine Market Size is valued at $8.9 Billion in 2025 and is forecast to reach $13.7 Billion in 2032 at a CAGR of 6.4%.
The Pneumococcal Vaccine Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Pneumococcal Vaccine Market segments across 22 countries from 2021 to 2032. Key segments covered include By Vaccine (Pneumococcal conjugate vaccine, Pneumococcal polysaccharide vaccine), By Product (Prevnar 13, Synflorix, Pneumovax23), By Distribution Channel (Distribution partner companies, Non-governmental Organizations, Government Authorities), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Pneumococcal Vaccine Market Insights, 2025
The pneumococcal vaccine market continues to expand, driven by enhanced vaccine formulations covering more serotypes and improved immunization strategies globally. Recent developments include next-generation conjugate vaccines with broader serotype coverage aimed at reducing invasive pneumococcal diseases across all age groups. The incorporation of protein-based antigens is under clinical evaluation to elicit longer-lasting immune responses. Efforts to improve vaccine accessibility in low- and middle-income countries have accelerated, supported by global health initiatives and partnerships. Innovations in delivery methods, including needle-free and thermostable formulations, are enhancing immunization coverage and compliance. The market is also adapting to the evolving epidemiology of pneumococcal strains influenced by vaccination campaigns. Regulatory bodies are increasingly focusing on post-marketing surveillance to monitor vaccine effectiveness and safety. The COVID-19 pandemic underscored the importance of respiratory disease prevention, further propelling pneumococcal vaccine demand.
Five Trends Shaping the Global Pneumococcal Vaccine Market in 2025 and Beyond
The global Pneumococcal Vaccine Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Pneumococcal Vaccine Industry?
The Pneumococcal Vaccine Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Pneumococcal Vaccine Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Pneumococcal Vaccine Market Segment Insights
The Pneumococcal Vaccine Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Vaccine (Pneumococcal conjugate vaccine, Pneumococcal polysaccharide vaccine), By Product (Prevnar 13, Synflorix, Pneumovax23), By Distribution Channel (Distribution partner companies, Non-governmental Organizations, Government Authorities). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Pneumococcal Vaccine Industry Value Chain
The chapter identifies potential companies and their operations across the global Pneumococcal Vaccine Industry ecosystem. It assists decision-makers in evaluating global Pneumococcal Vaccine Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Pneumococcal Vaccine Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Pneumococcal Vaccine Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Pneumococcal Vaccine Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Pneumococcal Vaccine Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Pneumococcal Vaccine Market.
Europe Pneumococcal Vaccine Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Pneumococcal Vaccine Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Pneumococcal Vaccine Industry competitiveness. The report analyses the key Pneumococcal Vaccine Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Pneumococcal Vaccine Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Pneumococcal Vaccine Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Pneumococcal Vaccine Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Pneumococcal Vaccine Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Pneumococcal Vaccine Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Pneumococcal Vaccine Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Beijing Minhai Biotechnology Co.,Ltd, CSL Ltd, GlaxoSmithKline plc, Merck KGaA, Pfizer Inc, Sanofi S.A, Serum Institute of India Pvt. Ltd, Walvax Biotechnology Co. Ltd. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Pneumococcal Vaccine Market Scope
Leading Segments
By Vaccine
Pneumococcal conjugate vaccine
Pneumococcal polysaccharide vaccine
By Product
Prevnar 13
Synflorix
Pneumovax23
By Distribution Channel
Distribution partner companies
Non-governmental Organizations
Government Authorities
Leading Companies
Beijing Minhai Biotechnology Co.,Ltd
CSL Ltd
GlaxoSmithKline plc
Merck KGaA
Pfizer Inc
Sanofi S.A
Serum Institute of India Pvt. Ltd
Walvax Biotechnology Co. Ltd
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report
Table of Contents
193 Pages
- 1. Table of Contents
- List of Figures and Tables
- 2. Executive Summary
- 2.1 Key Highlights
- 2.1.1 Pneumococcal Vaccine Market Size Outlook, 2018-2024 and 2025-2032
- 2.1.2 Largest Pneumococcal Vaccine Market Types and Applications
- 2.1.3 Fastest Growing Segments
- 2.1.4 Potential Markets
- 2.1.5 Market Concentration
- 2.2 Market Scope and Segmentation
- 2.2.1 Market Scope- Segments
- 2.2.2 Market Scope- Countries
- 2.2.3 Macroeconomic and Demographic Outlook
- 2.2.4 Abbreviations
- 2.2.5 Units and Currency Conversions
- 3. Research Methodology
- 3.1 Primary Research Surveys
- 3.2 Secondary Data Sources
- 3.3 Data Triangulation
- 3.4 Forecast Methodology
- 3.5 Assumptions and Limitations
- 4. Introduction to Global Pneumococcal Vaccine Market in 2025
- 4.1 Industry Panorama
- 4.2 Leading Companies Profiled in the Study
- 4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
- 4.4 Market Dynamics
- 4.4.1 Market Dynamics- Trends and Drivers
- 4.4.2 Market Dynamics- Opportunities and Challenges
- 4.5 Regional Analysis
- 4.6 Porter’s Five Force Analysis
- 4.6.1 Intensity of Competitive Rivalry
- 4.6.2 Threat of New Entrants
- 4.6.3 Threat of Substitutes
- 4.6.4 Bargaining Power of Buyers
- 4.6.5 Bargaining Power of Suppliers
- 4.7 Pneumococcal Vaccine Market Industry Value Chain Analysis
- 4.7.1 Stage of Value Chain
- 4.7.2 Key Activities of Companies
- 4.7.3 Companies Included in Each Stage
- 4.7.4 Key Insights
- 5. Pneumococcal Vaccine Market Outlook to 2032
- 5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
- 5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
- 5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
- By Vaccine
- Pneumococcal conjugate vaccine
- Pneumococcal polysaccharide vaccine
- By Product
- Prevnar 13
- Synflorix
- Pneumovax23
- By Distribution Channel
- Distribution partner companies
- Non-governmental Organizations
- Government Authorities
- 6. Global Pneumococcal Vaccine Market Outlook across Growth Scenarios
- 6.1 Low Growth Scenario
- 6.2 Base/Reference Case
- 6.3 High Growth Scenario
- 6. North America Pneumococcal Vaccine Market Size Outlook
- 6.1 Key Market Statistics, 2024
- 6.2 North America Pneumococcal Vaccine Market Trends and Growth Opportunities
- 6.2.1 North America Pneumococcal Vaccine Market Outlook by Type
- 6.2.2 North America Pneumococcal Vaccine Market Outlook by Application
- 6.3 North America Pneumococcal Vaccine Market Outlook by Country
- 6.3.1 The US Pneumococcal Vaccine Market Outlook, 2021- 2032
- 6.3.2 Canada Pneumococcal Vaccine Market Outlook, 2021- 2032
- 6.3.3 Mexico Pneumococcal Vaccine Market Outlook, 2021- 2032
- 7. Europe Pneumococcal Vaccine Market Size Outlook
- 7.1 Key Market Statistics, 2024
- 7.2 Europe Pneumococcal Vaccine Market Trends and Growth Opportunities
- 7.2.1 Europe Pneumococcal Vaccine Market Outlook by Type
- 7.2.2 Europe Pneumococcal Vaccine Market Outlook by Application
- 7.3 Europe Pneumococcal Vaccine Market Outlook by Country
- 7.3.2 Germany Pneumococcal Vaccine Market Outlook, 2021- 2032
- 7.3.3 France Pneumococcal Vaccine Market Outlook, 2021- 2032
- 7.3.4 The UK Pneumococcal Vaccine Market Outlook, 2021- 2032
- 7.3.5 Spain Pneumococcal Vaccine Market Outlook, 2021- 2032
- 7.3.6 Italy Pneumococcal Vaccine Market Outlook, 2021- 2032
- 7.3.7 Russia Pneumococcal Vaccine Market Outlook, 2021- 2032
- 7.3.8 Rest of Europe Pneumococcal Vaccine Market Outlook, 2021- 2032
- 8. Asia Pacific Pneumococcal Vaccine Market Size Outlook
- 8.1 Key Market Statistics, 2024
- 8.2 Asia Pacific Pneumococcal Vaccine Market Trends and Growth Opportunities
- 8.2.1 Asia Pacific Pneumococcal Vaccine Market Outlook by Type
- 8.2.2 Asia Pacific Pneumococcal Vaccine Market Outlook by Application
- 8.3 Asia Pacific Pneumococcal Vaccine Market Outlook by Country
- 8.3.1 China Pneumococcal Vaccine Market Outlook, 2021- 2032
- 8.3.2 India Pneumococcal Vaccine Market Outlook, 2021- 2032
- 8.3.3 Japan Pneumococcal Vaccine Market Outlook, 2021- 2032
- 8.3.4 South Korea Pneumococcal Vaccine Market Outlook, 2021- 2032
- 8.3.5 Australia Pneumococcal Vaccine Market Outlook, 2021- 2032
- 8.3.6 South East Asia Pneumococcal Vaccine Market Outlook, 2021- 2032
- 8.3.7 Rest of Asia Pacific Pneumococcal Vaccine Market Outlook, 2021- 2032
- 9. South America Pneumococcal Vaccine Market Size Outlook
- 9.1 Key Market Statistics, 2024
- 9.2 South America Pneumococcal Vaccine Market Trends and Growth Opportunities
- 9.2.1 South America Pneumococcal Vaccine Market Outlook by Type
- 9.2.2 South America Pneumococcal Vaccine Market Outlook by Application
- 9.3 South America Pneumococcal Vaccine Market Outlook by Country
- 9.3.1 Brazil Pneumococcal Vaccine Market Outlook, 2021- 2032
- 9.3.2 Argentina Pneumococcal Vaccine Market Outlook, 2021- 2032
- 9.3.3 Rest of South and Central America Pneumococcal Vaccine Market Outlook, 2021- 2032
- 10. Middle East and Africa Pneumococcal Vaccine Market Size Outlook
- 10.1 Key Market Statistics, 2024
- 10.2 Middle East and Africa Pneumococcal Vaccine Market Trends and Growth Opportunities
- 10.2.1 Middle East and Africa Pneumococcal Vaccine Market Outlook by Type
- 10.2.2 Middle East and Africa Pneumococcal Vaccine Market Outlook by Application
- 10.3 Middle East and Africa Pneumococcal Vaccine Market Outlook by Country
- 10.3.1 Saudi Arabia Pneumococcal Vaccine Market Outlook, 2021- 2032
- 10.3.2 The UAE Pneumococcal Vaccine Market Outlook, 2021- 2032
- 10.3.3 Rest of Middle East Pneumococcal Vaccine Market Outlook, 2021- 2032
- 10.3.4 South Africa Pneumococcal Vaccine Market Outlook, 2021- 2032
- 10.3.5 Egypt Pneumococcal Vaccine Market Outlook, 2021- 2032
- 10.3.6 Rest of Africa Pneumococcal Vaccine Market Outlook, 2021- 2032
- 11. Company Profiles
- 11.1 Leading 10 Companies
- Beijing Minhai Biotechnology Co.,Ltd
- CSL Ltd
- GlaxoSmithKline plc
- Merck KGaA
- Pfizer Inc
- Sanofi S.A
- Serum Institute of India Pvt. Ltd
- Walvax Biotechnology Co. Ltd
- 11.2 Overview
- 11.3 Products and Services
- 11.4 SWOT Profile
- 12. Appendix
- 12.1 Subscription Options
- 12.2 Customization Options
- 12.3 Publisher Details
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
